Applicability of epigenetic age models to next-generation methylation arrays.

IF 10.4 1区 生物学 Q1 GENETICS & HEREDITY
Leonardo D Garma, Miguel Quintela-Fandino
{"title":"Applicability of epigenetic age models to next-generation methylation arrays.","authors":"Leonardo D Garma, Miguel Quintela-Fandino","doi":"10.1186/s13073-024-01387-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Epigenetic clocks are mathematical models used to estimate epigenetic age based on DNA methylation at specific CpG sites. As new methylation microarrays are developed and older models discontinued, existing epigenetic clocks might become obsolete. Here, we explored the effects of the changes introduced in the new EPICv2 DNA methylation array on existing epigenetic clocks.</p><p><strong>Methods: </strong>We tested the performance of four epigenetic clocks on the probeset of the EPICv2 array using a dataset of 10,835 samples. We developed a new epigenetic age prediction model compatible across the 450 k, EPICv1, and EPICv2 microarrays and validated it on 2095 samples. We estimated technical noise and intra-subject variation using two datasets with repeated sampling. We used data from (i) cancer survivors who had undergone different therapies, (ii) breast cancer patients and controls, and (iii) an exercise-based interventional study, to test the ability of our model to detect alterations in epigenetic age acceleration in response to theoretically antiaging interventions.</p><p><strong>Results: </strong>The results of the four epiclocks tested are significantly distorted by the EPICv2 probeset, causing an average difference of up to 25 years. Our new model produced highly accurate chronological age predictions, comparable to a state-of-the-art epiclock. The model reported the lowest epigenetic age acceleration in normal populations, as well as the lowest variation across technical replicates and repeated samples from the same subjects. Finally, our model reproduced previous results of increased epigenetic age acceleration in cancer patients and in survivors treated with radiation therapy, and no changes from exercise-based interventions.</p><p><strong>Conclusion: </strong>Existing epigenetic clocks require updates for full EPICv2 compatibility. Our new model translates the capabilities of state-of-the-art epigenetic clocks to the EPICv2 platform and is cross-compatible with older microarrays. The characterization of epigenetic age prediction variation provides useful metrics to contextualize the relevance of epigenetic age alterations. The analysis of data from subjects influenced by radiation, cancer, and exercise-based interventions shows that despite being good predictors of chronological age, neither a pathological state like breast cancer, a hazardous environmental factor (radiation), nor exercise (a beneficial intervention) caused significant changes in the values of the \"epigenetic age\" determined by these first-generation models.</p>","PeriodicalId":12645,"journal":{"name":"Genome Medicine","volume":"16 1","pages":"116"},"PeriodicalIF":10.4000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460231/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Genome Medicine","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1186/s13073-024-01387-4","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Epigenetic clocks are mathematical models used to estimate epigenetic age based on DNA methylation at specific CpG sites. As new methylation microarrays are developed and older models discontinued, existing epigenetic clocks might become obsolete. Here, we explored the effects of the changes introduced in the new EPICv2 DNA methylation array on existing epigenetic clocks.

Methods: We tested the performance of four epigenetic clocks on the probeset of the EPICv2 array using a dataset of 10,835 samples. We developed a new epigenetic age prediction model compatible across the 450 k, EPICv1, and EPICv2 microarrays and validated it on 2095 samples. We estimated technical noise and intra-subject variation using two datasets with repeated sampling. We used data from (i) cancer survivors who had undergone different therapies, (ii) breast cancer patients and controls, and (iii) an exercise-based interventional study, to test the ability of our model to detect alterations in epigenetic age acceleration in response to theoretically antiaging interventions.

Results: The results of the four epiclocks tested are significantly distorted by the EPICv2 probeset, causing an average difference of up to 25 years. Our new model produced highly accurate chronological age predictions, comparable to a state-of-the-art epiclock. The model reported the lowest epigenetic age acceleration in normal populations, as well as the lowest variation across technical replicates and repeated samples from the same subjects. Finally, our model reproduced previous results of increased epigenetic age acceleration in cancer patients and in survivors treated with radiation therapy, and no changes from exercise-based interventions.

Conclusion: Existing epigenetic clocks require updates for full EPICv2 compatibility. Our new model translates the capabilities of state-of-the-art epigenetic clocks to the EPICv2 platform and is cross-compatible with older microarrays. The characterization of epigenetic age prediction variation provides useful metrics to contextualize the relevance of epigenetic age alterations. The analysis of data from subjects influenced by radiation, cancer, and exercise-based interventions shows that despite being good predictors of chronological age, neither a pathological state like breast cancer, a hazardous environmental factor (radiation), nor exercise (a beneficial intervention) caused significant changes in the values of the "epigenetic age" determined by these first-generation models.

表观遗传年龄模型对下一代甲基化阵列的适用性。
背景:表观遗传时钟是一种数学模型,用于根据特定 CpG 位点的 DNA 甲基化情况估计表观遗传年龄。随着新甲基化微阵列的开发和旧模型的停用,现有的表观遗传时钟可能会过时。在此,我们探讨了新的 EPICv2 DNA 甲基化阵列引入的变化对现有表观遗传时钟的影响:我们使用 10,835 个样本的数据集测试了 EPICv2 阵列探针集上四种表观遗传时钟的性能。我们开发了一种新的表观遗传年龄预测模型,兼容450 k、EPICv1和EPICv2微阵列,并在2095个样本上进行了验证。我们利用两个重复采样的数据集估算了技术噪声和受试者内变异。我们使用了来自(i)接受过不同疗法的癌症幸存者、(ii)乳腺癌患者和对照组以及(iii)基于运动的干预研究的数据,以检验我们的模型检测表观遗传年龄加速度变化对理论上的抗衰老干预措施的响应能力:结果:EPICv2 探测集严重扭曲了四项表观遗传学测试的结果,造成的平均年龄差异高达 25 岁。我们的新模型能预测出非常准确的年代年龄,可与最先进的外显子锁相媲美。该模型报告了正常人群中最低的表观遗传年龄加速度,以及技术重复和同一受试者重复样本间最低的差异。最后,我们的模型再现了之前的结果,即癌症患者和接受过放射治疗的幸存者的表观遗传年龄加速度增加,而运动干预则没有变化:结论:现有的表观遗传时钟需要更新才能与 EPICv2 完全兼容。我们的新模型将最先进的表观遗传时钟的功能转化到了 EPICv2 平台上,并与旧的微阵列交叉兼容。表观遗传年龄预测变异的特征为表观遗传年龄改变的相关性提供了有用的衡量标准。对受辐射、癌症和运动干预影响的受试者数据的分析表明,尽管表观年龄是很好的预测指标,但乳腺癌等病理状态、有害环境因素(辐射)和运动(一种有益的干预)都不会导致这些第一代模型确定的 "表观遗传年龄 "值发生显著变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Genome Medicine
Genome Medicine GENETICS & HEREDITY-
CiteScore
20.80
自引率
0.80%
发文量
128
审稿时长
6-12 weeks
期刊介绍: Genome Medicine is an open access journal that publishes outstanding research applying genetics, genomics, and multi-omics to understand, diagnose, and treat disease. Bridging basic science and clinical research, it covers areas such as cancer genomics, immuno-oncology, immunogenomics, infectious disease, microbiome, neurogenomics, systems medicine, clinical genomics, gene therapies, precision medicine, and clinical trials. The journal publishes original research, methods, software, and reviews to serve authors and promote broad interest and importance in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信